EFTA Document EFTA01461474

Nasdaq Biotech Index (NBI) dropped 4.4% Friday Sharpest decline since Oct-11 • Triggered by a letter from congressional representatives to a biotech company Gilead Sciences, questioning its plans to sell a hepatitis C drug (named Sovaldi) for 584,000 per dose Gilead required to give briefing by 03-Apr • Sovaldi expected to generate >S4bn in sales this year The drug's expense might saddle state Medicaid programs with steep Costs The whole sector is as risk us is the only major health-